The Wegovy 1.7mg click chart explained

How the click system works on the Wegovy pen at 1.7mg

The Wegovy pre-filled injection pen uses a dose-selection mechanism that produces distinct, countable clicks as you turn the dial. Each dose strength maps to a set number of clicks, and the click chart circulating online is simply a visual summary of those counts drawn from the official Wegovy SmPC and Patient Information Leaflet on the eMC. The leaflet inside your box is the authoritative source; the chart is a memory aid, not a replacement for it.

At 1.7mg you are further along the titration schedule than most people expect to be when they first research this question. The clicks you count should match what your prescriber confirmed during dose-increase review. If the count feels different from a previous pen batch, or if the dial is stiff or does not click cleanly, do not inject and contact your pharmacy. A faulty pen mechanism is the kind of thing worth a quick one-minute check before every injection: hold the pen up, dial slowly, and count out loud against the number in your leaflet before attaching the needle.

Injection sites remain the same at this dose: the abdomen, thigh or upper arm, rotating each week. Your prescriber or the leaflet will confirm exactly where on the body each site boundary sits. Storage stays refrigerated at 2–8°C; once in use, follow the room-temperature window printed on the carton rather than any figure quoted online, because batch-specific guidance takes precedence.

Where 1.7mg sits in the evidence on semaglutide for weight management

The STEP 1 trial, published in the New England Journal of Medicine, studied semaglutide 2.4mg against placebo over 68 weeks in adults with obesity. Participants reached 2.4mg through a titration schedule that passed through 1.7mg as a penultimate step. Average weight reduction at 2.4mg maintenance was around 15% of body weight, a figure that belongs to the full trial programme, not to the 1.7mg dose specifically.

That distinction matters. The 1.7mg step is a bridge, not a destination for most people. Its job is to help your body adapt to semaglutide's effects (appetite suppression, slowed gastric emptying and the accompanying gastrointestinal adjustment) before the full maintenance dose. Nausea, which tends to be most noticeable after each step up, often begins to settle within a couple of weeks at a stable dose. Some people find 1.7mg is where their GI side effects are most pronounced; that is normal and usually temporary.

For context on how the full titration fits together, our overview of Wegovy doses covers each stage of the schedule and what the evidence shows at maintenance.

Your prescriber decides whether to move to 2.4mg, here is why

The licensed schedule is not a conveyor belt. NHS England's guidance on weight-management injections is clear that titration should be guided by tolerability and clinical response, with the prescriber assessing each step. Staying at 1.7mg for longer than one month is a clinical decision, not a failure. If side effects at this dose are significant, your prescriber may advise staying put rather than moving up on the standard four-week schedule.

Moving to 2.4mg (the standard maintenance dose, and the one on which the headline trial results are based) is something a real clinician reviews, not an automated prompt in an app. At nume, a GPhC-registered prescriber on our clinical team reviews dose-increase requests against your reported weight, tolerance and any side effects before approving the next pen. That evidence requirement exists for patient safety, not bureaucracy.

If you are already at 2.4mg and want to understand the click count at that maintenance level, our Wegovy 2.4mg click chart page covers it in the same format. For those still earlier in the schedule, the 1.0mg click guide explains the previous step.

What 1.7mg means for the wider picture of your treatment

Reaching 1.7mg means you have already worked through three dose steps. That takes time (a minimum of three months from the 0.25mg starting dose, assuming no delays) and it reflects a genuine clinical commitment. Most people at this stage are beginning to notice meaningful changes in appetite and, for many, early weight loss. If you want to understand what comes next, our page on the 1.75mg Wegovy dose explains how that stage fits into the schedule and what to expect.

The side-effect profile at 1.7mg mirrors the rest of the schedule: nausea, loose stools, constipation or reflux are the most commonly reported, typically linked to dose changes rather than stable dosing. Persistent, severe stomach pain that radiates to the back is different and needs urgent medical attention, it can be a sign of pancreatitis, which the MHRA highlighted in a Drug Safety Update for GLP-1 medicines. Report any suspected side effects, and any concerns about your pen or its source, via the MHRA Yellow Card scheme.

If you are thinking about starting Wegovy and want to understand the full cost picture before committing, our guide to Wegovy pricing in the UK sets out what private treatment actually costs and what a legitimate price should include. Those earlier in the titration process may also find our Wegovy 0.5mg click chart useful for checking the correct dial count at that lower dose. When you are ready to speak to a prescriber, the place to start is a free consultation with our clinical team.